Cargando…

Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis

BACKGROUND: The aim of the study is to reveal the contribution of complete response (CR) to treatment to overall survival (OS) in patients with unresectable metastatic colorectal cancer. In addition, to evaluate progression-free survival (PFS) in patients who attained CR to treatment and to examine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bulut, Gulcan, Guner Oytun, Merve, Almuradova, Elvina, Harman, Mustafa, Uslu, Ruchan, Karabulut, Bulent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575296/ https://www.ncbi.nlm.nih.gov/pubmed/34748587 http://dx.doi.org/10.1371/journal.pone.0259622

Ejemplares similares

Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study
por: Almuradova, Elvina, et al.
Publicado: (2023)

Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?
por: Ergun, Yakup, et al.
Publicado: (2020)

Pazopanib: a novel treatment option for aggressive fibromatosis
por: Bulut, Gulcan, et al.
Publicado: (2016)

Cancer-related hypercalcemia and potential treatments
por: Almuradova, Elvina, et al.
Publicado: (2023)

Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy
por: HOPANCI BIÇAKLI, Derya, et al.
Publicado: (2019)

Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer
por: Karabulut, Bulent, et al.
Publicado: (2010)

Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145
por: Kucukzeybek, Yuksel, et al.
Publicado: (2008)

The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer
por: Zhao, Jiemin, et al.
Publicado: (2017)

Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer
por: Yang, Yi, et al.
Publicado: (2020)

Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
por: Lee, Suk-young, et al.
Publicado: (2016)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
por: Aparicio, Jorge, et al.
Publicado: (2020)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

Unresectable cutaneous metastatic tumor in the arm that underwent complete remission after radiotherapy
por: Oike, Takahiro, et al.
Publicado: (2020)

Utility of the quasi‐monomorphic variation range in unresectable metastatic colorectal cancer patients
por: Bando, Hideaki, et al.
Publicado: (2018)

Letter to editor: is laboratory index really a practical and valid tool to predict mortality?
por: Oytun, Merve Güner, et al.
Publicado: (2021)

Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy
por: Faruk Aykan, N., et al.
Publicado: (2013)

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020)

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
por: Van Cutsem, E., et al.
Publicado: (2022)

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
por: Kato, Takeshi, et al.
Publicado: (2023)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Clinical Outcomes of Upfront Primary Tumor Resection in Synchronous Unresectable Metastatic Colorectal Cancer
por: Shin, Ji Eun, et al.
Publicado: (2023)

Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer
por: Ziemons, Janine, et al.
Publicado: (2023)

Percutaneous laser ablation: a new contribution to unresectable high-risk metastatic retroperitoneal lesions?
por: Jiang, Tian’an, et al.
Publicado: (2016)

Frailty in community-dwelling older adults: reliability and validity of the Turkish version of the Gérontopôle frailty screening tool
por: CEYLAN, Serdar, et al.
Publicado: (2022)

The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer
por: Shibutani, Masatsune, et al.
Publicado: (2015)

The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer
por: Shibutani, Masatsune, et al.
Publicado: (2016)

The Impact of Primary Tumor Resection on Survival in Asymptomatic Colorectal Cancer Patients With Unresectable Metastases
por: Doah, Ki Yoon, et al.
Publicado: (2021)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

Case Report—Staged brachytherapy achieving complete metabolic response in unresectable oligometastatic colorectal cancer to the liver
por: Appalanaido, Gokula Kumar, et al.
Publicado: (2021)

Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival
por: Homayounfar, K., et al.
Publicado: (2013)

Contribution of DECT in detecting serosal invasion of gastric cancer
por: KÜPELİ, Ali, et al.
Publicado: (2019)

Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis
por: Dendy, Meaghan S., et al.
Publicado: (2017)

Primary Tumor Resection in Asymptomatic Colorectal Cancer Patients With Unresectable Metastases: Can It Improve Survival?
por: Ihn, Myong Hoon
Publicado: (2021)

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2016)

Relationships of Fall Risk With Frailty, Sarcopenia, and Balance Disturbances in Mild-to-Moderate Alzheimer’s Disease
por: Güner Oytun, Merve, et al.
Publicado: (2023)

Programmed Chemotherapy for Patients with Metastatic Unresectable Gastric Cancer
por: Shinoda, Masataka, et al.
Publicado: (2012)

Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions
por: Boyce-Fappiano, David, et al.
Publicado: (2022)

PROTOCOL FOR LIVER TRANSPLANTATION IN UNRESECTABLE COLORECTAL METASTASIS
por: ERNANI, Lucas, et al.
Publicado: (2022)

Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India
por: Kulkarni, Suyash, et al.
Publicado: (2017)

Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment
por: Wang, Feng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vdr1dil061i12da0dspph7teha